Bronchial reactivity to histamine before and after sodium cromoglycate in bronchial asthma

Bann Kang, C. K. Lee, Betty Miller Kolotkin, Robert G. Townley

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Out of 19 patients with extrinsic bronchial asthma challenged with 123 μg histamine acid phosphate by intravenous infusion only 13 responded with a fall in FEV1 of over 10% (mean 16%). Seventeen of these patients were given histamine 2 mg/ml by aerosol, and all responded with a mean decrease in FEVi of 37.8%. When challenged with allergen extract by aerosol the mean decrease in FEVi was 37.5%. After 40 mg sodium cromoglycate 15 of the 17 patients showed significant protection against allergen challenge with a mean decrease in FEV1 of only 23.6%. Inhalation of 40 mg sodium cromoglycate, however, failed to protect against histamine given by either the intravenous or aerosol route. Histamine given intravenously to asthmatic patients produces less of a bronchial response than when given by aerosol, even though the intravenous route produces many more systemic symptoms, such as flushing and throbbing headache. The protection of sodium cromoglycate against an allergen inhalation challenge is not due to histamine antagonism.

Original languageEnglish (US)
Pages (from-to)867-870
Number of pages4
JournalBritish Medical Journal
Issue number6014
StatePublished - Apr 10 1976

All Science Journal Classification (ASJC) codes

  • Medicine(all)


Dive into the research topics of 'Bronchial reactivity to histamine before and after sodium cromoglycate in bronchial asthma'. Together they form a unique fingerprint.

Cite this